Alamar Biosciences
Tracked across 2 events · 15 articles · First seen Mar 17, 2026 · Last active Apr 20, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Tech
Alamar Biosciences launched its NULISAseq Neuro 220 Panel, expanding its offerings for neurodegenerative disease research. This product launch is expected to enhance Alamar Biosciences' position in precision proteomics and contribute to its growth.
Mar 17, 2026 · 7 articles
Business
Alamar Biosciences successfully closed its upsized initial public offering, raising approximately $219.9 million. Its shares began trading on the Nasdaq Global Select Market under the ticker symbol 'ALMR', indicating a positive market reception and increased capital for its operations.
Apr 17, 2026 · 8 articles
100
Alamar Biosciences closed upsized initial public offeringAlamar Biosciences Upsized...
90
Alamar Biosciences began trading shares NasdaqAlamar Biosciences Upsized...
60
JPMorgan Chase===JPMorgan Chase acted as joint book-running manager Alamar BiosciencesAlamar Biosciences Upsized...
60
Bank of America acted as joint book-running manager Alamar BiosciencesAlamar Biosciences Upsized...
60
Toronto-Dominion Bank===TD Cowen acted as joint book-running manager Alamar BiosciencesAlamar Biosciences Upsized...
60
SVB Leerink===Leerink Partners acted as joint book-running manager Alamar BiosciencesAlamar Biosciences Upsized...
60
Stifel acted as joint book-running manager Alamar BiosciencesAlamar Biosciences Upsized...
10
United States===United States Securities and Exchange Commission made registration statements effective Alamar BiosciencesAlamar Biosciences Upsized...
Yuling Luo
CEO
↔
Alamar Biosciences
Yuling Luo is the founder, chairman, and chief executive officer of Alamar Biosc
NEWSDESK
Track Alamar Biosciences live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard